Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Provided By GlobeNewswire
Last update: Apr 15, 2025
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 -
- Additional clinical data from CRDF-004 trial expected in 1H 2025 -
Read more at globenewswire.com3.02
-0.68 (-18.38%)
Find more stocks in the Stock Screener
CRDF Latest News and Analysis
a day ago - ChartmillTop movers in Tuesday's after hours sessionWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
